Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.